News agency Bloomberg is reporting that AbbVie has dropped its legal action against the EMA following a compromise agreement.
The company brought the action in the EU General Court in 2013, to prevent the EMA from disclosing data relating to Humira to organisations including competing pharma companies. The compromise agreement will result in much of the data being released, but specific sections being withheld. This seems to be in accordance with the EMA’s new policy on data transparency, which came into effect in January 2014.
The announcement also comes hours after the European Parliament voted to pass the text of a new Regulation, which makes provision for increased transparency around clinical trial data.